XML 48 R38.htm IDEA: XBRL DOCUMENT
v3.25.1

Segments (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2025
Summary of Segment Profit | a. Segment information:
|  | Three months ended March 31, |
|  | 2025 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 1,910 |  |  | $ | 1,194 |  |  | $ | 582 |
Cost of sales |  |  | 851 |  |  |  | 536 |  |  |  | 304 |
R&D expenses |  |  | 154 |  |  |  | 60 |  |  |  | 25 |
S&M expenses |  |  | 273 |  |  |  | 199 |  |  |  | 118 |
G&A expenses |  |  | 96 |  |  |  | 69 |  |  |  | 39 |
Other |  |  | 3 |  |  |  | § |  |  |  | (1 | )
Segment profit |  | $ | 532 |  |  | $ | 329 |  |  | $ | 97 |
§ | Represents an amount less than $0.5 million.
|  | Three months ended March 31, |
|  | 2024 |
|  | United States |  |  | Europe |  |  | International Markets |
|  | (U.S. $ in millions) |
Revenues |  | $ | 1,725 |  |  | $ | 1,272 |  |  | $ | 597 |
Cost of sales |  |  | 867 |  |  |  | 534 |  |  |  | 300 |
R&D expenses |  |  | 154 |  |  |  | 56 |  |  |  | 28 |
S&M expenses |  |  | 261 |  |  |  | 194 |  |  |  | 118 |
G&A expenses |  |  | 93 |  |  |  | 65 |  |  |  | 35 |
Other |  |  | 1 |  |  |  | 1 |  |  |  | § |
Segment profit |  | $ | 350 |  |  | $ | 423 |  |  | $ | 117 |
§ | Represents an amount less than $0.5 million.
The following table presents a reconciliation of Teva’s segment profits to its consolidated operating income (loss) and to consolidated income (loss) before income taxes for the three months ended March 31, 2025 and 2024:
|  | Three months ended |
|  | March 31, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
United States profit |  | $ | 532 |  |  | $ | 350 |
Europe profit |  |  | 329 |  |  |  | 423 |
International Markets profit |  |  | 97 |  |  |  | 117 |
Total reportable segments profit |  |  | 958 |  |  |  | 890 |
Profit (loss) of other activities |  |  | (13 | ) |  |  | 2 |
Amounts not allocated to segments: |  |  |  |  |  |  |  |
Amortization |  |  | 145 |  |  |  | 152 |
Other assets impairments, restructuring and other items |  |  | (22 | ) |  |  | 673 |
Intangible assets impairments |  |  | 121 |  |  |  | 80 |
Legal settlements and loss contingencies |  |  | 83 |  |  |  | 106 |
Other unallocated amounts |  |  | 99 |  |  |  | 99 |
Consolidated operating income (loss) |  |  | 519 |  |  |  | (218 | )
Financial expenses, net |  |  | 225 |  |  |  | 250 |
Consolidated income (loss) before income taxes |  | $ | 294 |  |  | $ | (467 | )
Schedule Of Consolidated Income Before Income Tax | The following tables present revenues by major products and activities for the three months ended March 31, 2025 and 2024:
United States |  | Three months ended March 31, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including biosimilars) |  | $ | 849 |  |  | $ | 808 |
AJOVY ® |  |  | 53 |  |  |  | 45 |
AUSTEDO |  |  | 396 |  |  |  | 282 |
BENDEKA ® and TREANDA ® |  |  | 36 |  |  |  | 46 |
COPAXONE |  |  | 54 |  |  |  | 30 |
UZEDY |  |  | 39 |  |  |  | 15 |
Anda |  |  | 373 |  |  |  | 381 |
Other |  |  | 109 |  |  |  | 117 |
Total |  | $ | 1,910 |  |  | $ | 1,725 |
Europe |  | Three months ended March 31, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 989 |  |  | $ | 1,004 |
AJOVY |  |  | 58 |  |  |  | 51 |
COPAXONE |  |  | 42 |  |  |  | 57 |
Respiratory products |  |  | 55 |  |  |  | 66 |
Other |  |  | 50 |  |  |  | 94 |
Total |  | $ | 1,194 |  |  | $ | 1,272 |
International markets |  | Three months ended March 31, |
|  | 2025 |  |  | 2024 |
|  | (U.S. $ in millions) |
Generic products (including OTC and biosimilars) |  | $ | 468 |  |  | $ | 477 |
AJOVY |  |  | 28 |  |  |  | 17 |
AUSTEDO |  |  | 15 |  |  |  | 14 |
COPAXONE |  |  | 10 |  |  |  | 12 |
Other* |  |  | 61 |  |  |  | 77 |
Total |  | $ | 582 |  |  | $ | 597 |
* | Other revenues in the first quarter of 2025 include the sale of certain product rights.

X
- Definition Schedule of consolidated income before income tax. + References No definition available. + Details
Name: | teva_ScheduleOfConsolidatedIncomeBeforeIncomeTaxTableTextBlock
Namespace Prefix: | teva_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration